Publications by authors named "S Sirdesai"
Article Synopsis
- - MEDI2228 is an antibody drug conjugate designed to target B-cell maturation antigen (BCMA) and was tested in a phase 1 trial for patients with relapsed/refractory multiple myeloma after prior treatments with standard medications.
- - The trial involved 107 patients, identifying a maximum tolerated dose of 0.14 mg/kg every three weeks, with common side effects including photophobia, rash, and thrombocytopenia; two patients experienced serious dose-limiting toxicities.
- - Although MEDI2228 showed promising efficacy with a 56.1% objective response rate in one treatment group, ocular toxicity issues led to the decision not to pursue further development of the drug.
Background: JAK2-mutated polycythaemia vera (PV) is associated with reduced survival because of thrombotic events and haematological disease transformation. Therapeutic venesection has traditionally been used to lower haematocrit, but the technique of erythrocytapheresis has emerged over the last decade.
Aim: To compare erythrocytapheresis with venesection as treatment for PV by assessing medical efficacy and financial viability.
We evaluated the efficacy and tolerability of continuous ixazomib-thalidomide-dexamethasone (ITd: 4 mg, day 1, 8, 15; 100 mg daily; and 40 mg weekly). A total of 39 patients with relapsed/refractory multiple myeloma (RRMM) aged ≥18 years with one to three prior lines of therapy were enrolled from two tertiary centres in Victoria and South Australia, Australia. The overall response rate (ORR) was 56·4% with a clinical benefit rate of 71·8%.
View Article and Find Full Text PDF